Is Bristol-Myers Squibb (BMY) overvalued or fairly valued?

MarketChacha shows Bristol-Myers Squibb's valuation in context — a trailing P/E of about 13.9, a forward P/E of about 9.9, a price-to-book of about 5.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Bristol-Myers Squibb's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (7.05×) from reported figures — education, not a rating.

What is Bristol-Myers Squibb's revenue?

Bristol-Myers Squibb reported revenue of $48.2B for FY2025, with net profit of $7.1B, per official filings.

What is the share price of Bristol-Myers Squibb (BMY)?

Bristol-Myers Squibb last traded at $64.84 (+0.2% on the day), as of 8/10/2026 — a delayed quote shown for education, not investment advice.

Bristol-Myers Squibb

BMY · NYSE · Pharma · United States

Snapshot

TickerBMY

ExchangeNYSE

SectorPharma

IndustryDrug Manufacturers - General

CountryUnited States

Employees32,500

HeadquartersPrinceton, United States

Websitewww.bms.com

Filings tracked16

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Who owns it

Insiders0.1%
Institutions84.8%
Public & other15.1%

3,259 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.83%
Vanguard Capital Management LLC6.48%
State Street Corporation5.01%
JPMORGAN CHASE & CO4.53%
Charles Schwab Investment Management, Inc.2.99%
Geode Capital Management, LLC2.71%
Vanguard Portfolio Management LLC2.26%
Bank of America Corporation1.60%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 3.2 points over the period — profitability is trending down.

Cash conversion7.05×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend17.8% → 14.6%

Margin has compressed by about 3.2 points over the period — profitability is trending down.

Return on equity38.2%

Latest ROE of 38.2% — capital is generating a healthy return.

Growth qualityrev 3% · PAT -6%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $12.7B · EPS 1.59

Est. earnings growth +26.1%

Next fiscal year

Rev $48.1B · EPS 6.55

Est. earnings growth -5.7%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$48.2B

Net margin

14.6%

ROE

38.2%

Revenue CAGR (2y)

+3.5%

Profit CAGR (2y)

-6.2%

EPS (FY2025)

3.46

Net profit (FY2025)

$7.1B

Ask MarketChacha about BMY

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

On MarketChacha

Posts about BMY

Why did Replimune (REPL) double on Friday? An FDA panel said yesc/usmarkets · 8/1/2026▲ 0

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$48.2B	$7.1B	3.46	14.6%	38.2%
FY2024	$48.3B	$-8.9B	-4.41	-18.5%	-54.8%
FY2023	$45.0B	$8.0B	3.86	17.8%	27.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$13.0B	$3.3B	1.62	25.6%
2026Q1	$11.5B	$2.7B	1.31	23.3%
2025Q3	$12.2B	$2.2B	1.08	18.0%
2025Q2	$12.3B	$1.3B	0.64	10.7%
2025Q1	$11.2B	$2.5B	1.20	21.9%
2024Q3	$11.9B	$1.2B	0.60	10.2%
2024Q2	$12.2B	$1.7B	0.83	13.8%
2024Q1	$11.9B	$-11.9B	-5.89	-100.4%
2023Q3	$11.0B	$1.9B	0.93	17.6%
2023Q2	$11.2B	$2.1B	0.99	18.5%
2023Q1	$11.3B	$2.3B	1.07	20.0%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC7/30/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC7/30/2026material
8-K — Shareholder vote results
SEC5/8/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC4/30/2026material
10-Q filing
SEC4/30/2026
10-K filing
SEC2/11/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC2/5/2026material
8-K — Reg FD disclosure, Exhibits
SEC1/12/2026material

2025

8-K — Other events, Exhibits
SEC11/18/2025material
8-K — Other events, Exhibits
SEC11/10/2025material
8-K — Other events, Exhibits
SEC11/3/2025material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC10/30/2025material
10-Q filing
SEC10/30/2025
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC7/31/2025material
10-Q filing
SEC7/31/2025
8-K — Executive/director change, Exhibits
SEC7/25/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.